SEC Info - FSD Pharma Inc. - ‘6-K’ for 9/30/23

SEC Info℠

Home

Help

Please Sign In

FSD Pharma Inc. – ‘6-K’ for 9/30/23

On: Tuesday, 11/14/23, at 6:12pm ET · As of: 11/15/23 · For: 9/30/23 · Accession #: 1062993-23-20842 · File #: 1-39152

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/15/23  FSD Pharma Inc.                   6-K         9/30/23    5:1.1M                                   Newsfile Corp./FA

Current, Quarterly or Annual Report by a Foreign Issuer — Form 6-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML      9K 
                Issuer -- form6k                                                 
 2: EX-99.1     Miscellaneous Exhibit -- exhibit99-1                HTML    640K 
 3: EX-99.2     Miscellaneous Exhibit -- exhibit99-2                HTML    465K 
 4: EX-99.3     Miscellaneous Exhibit -- exhibit99-3                HTML      9K 
 5: EX-99.4     Miscellaneous Exhibit -- exhibit99-4                HTML      9K

‘6-K’ — Current, Quarterly or Annual Report by a Foreign Issuer — form6k

This is an HTML Document rendered as filed. [ Alternative Formats ]

FSD Pharma Inc.: Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2023

Commission File Number: 001-39152

FSD PHARMA INC.
(Translation of registrant's name into English)

199 Bay Street, Suite 4000
Toronto, Ontario
M5L 1A9
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		FSD Pharma Inc.
		(Registrant)


Date: November 14, 2023		By: /s/ *Nathan Coyle*
		Name: Nathan Coyle
		Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit		Description

99.1		Condensed Consolidated Interim Financial Statements for the period ended September 30, 2023
99.2		Management's Discussion and Analysis for the period ended September 30, 2023
99.3		Form 52-109F2 Certification of Interim Filings - CEO
99.4		Form 52-109F2 Certification of Interim Filings - CFO

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed as of:	11/15/23	None on these Dates
Filed on:	11/14/23
For Period end:	9/30/23
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/20/24  FSD Pharma Inc.                   424B5       2/16/24    1:863K                                   RDG Filings/FA
12/26/23  FSD Pharma Inc.                   F-3        12/22/23    5:33M                                    Blueprint/FA

↑Top

Filing Submission 0001062993-23-020842 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)